A comprehensive pooled analysis of four prospective neoadjuvant clinical trials involving 2310 patients showed a significantly lower pCR rate in HER2-low breast cancer than in HER2-null breast cancer (29.2% vs. 39.0%, p = 0.0002). Here, ERBB2 is linked to breast carcinoma.